Overview
FR260010 is a selective serotonin 5-HT2C receptor antagonist which was under development for the treatment of anxiety disorders but was never marketed. It is taken orally.
FR260010 is a selective serotonin 5-HT2C receptor antagonist which was under development for the treatment of anxiety disorders but was never marketed. It is taken orally.